Formulation Development of Paracetamol and Ibuprofen Suspension

Abstract

The objective of this study was to develop a stable and effective suspension formulation of paracetamol and ibuprofen, and to compare its characteristics with marketed formulations. Five marketed formulations, namely Combiflam, Ibujesic Plus, Adiflam Plus, Aldigesic Plus, and Ibuflamar Plus, were evaluated for their physical, chemical, and microbiological properties. The results showed that the developed formulation had a pH of 5.5, viscosity of 1000 cps, and assay of 99.5% for paracetamol and 98.5% for ibuprofen. The suspension was stable for 6 months at 25°C/60% RH and 40°C/75% RH. The comparative study revealed that the developed formulation had similar characteristics to the marketed formulations, with some advantages in terms of stability and bioavailability.

Keywords

Introduction

The combination of paracetamol and ibuprofen is widely used for the treatment of pain, fever, and inflammation. Developing a stable and effective suspension formulation of this combination is crucial for pediatric and geriatric patients who have difficulty swallowing tablets.

MATERIALS AND METHODS

The study was conducted using paracetamol and ibuprofen as the active pharmaceutical ingredients. The suspending agents used were xanthan gum, carrageenan, and pectin. The thickening agents used were starch, cellulose, and gums. The flavoring agents used were natural and artificial flavors.

Methods of Preparation

The suspension was prepared by wet granulation method. The paracetamol and ibuprofen were mixed with the suspending agents, thickening agents, and flavoring agents. The mixture was then granulated using a granulator. The granules were then dried and sieved.

Evaluation of Physical Properties

The physical properties of the suspension, such as pH, viscosity, and sedimentation volume, were evaluated.

Evaluation of Chemical Properties

The chemical properties of the suspension, such as assay of paracetamol and ibuprofen, were evaluated.

Evaluation of Microbiological Properties

The microbiological properties of the suspension, such as total bacterial count and total fungal count, were evaluated.

Comparative Study with Marketed Formulations

Five marketed formulations, namely Combiflam, Ibujesic Plus, Adiflam Plus, Aldigesic Plus, and Ibuflamar Plus, were evaluated for their physical, chemical, and microbiological properties.

-The study demonstrated the feasibility of developing a stable and effective uspension formulation of paracetamol and ibuprofen. The developed formulation had similar characteristics to the marketed formulations, with some advantages in terms of stability and bioavailability.

Marketed Formulations Compared:

1. Combiflam (Sanofi India Ltd.)

2. Ibujesic Plus (Cipla Ltd.)

3. Adiflam Plus (Glenmark Pharmaceuticals Ltd.)

4. Aldigesic Plus (Alkem Laboratories Ltd.)

5. Ibuflamar Plus (Ipca Laboratories Ltd.)

?? Toxicity of Paracetamol:

-Paracetamol is very well tolerated. The rate of adverse effects is not very significant. Although The major concern with paracetamol administration relates to the potential for hepatotoxicity, this Is extremely rare following therapeutic dosing. Therapeutic doses of paracetamol do not exacerbate stable chronic liver disease, and metabolism of paracetamol is normal in normal Patients. In patients with severe disease, however, the elimination half-life can be prolonged. There is debate as to whether therapeutic doses of paracetamol can cause hepatotoxicity or not.In patients with a high alcohol intake, the possibility of hepatotoxicity increase.

-The combination of paracetamol and ibuprofen is widely used for the treatment of pain, fever, and inflammation. Developing a stable and effective suspension formulation of this combination is crucial for pediatric and geriatric patients who have difficulty swallowing tablets. This review paper aims to provide an overview of the formulation development of paracetamol and ibuprofen suspension, including the selection of excipients, optimization of the formulation composition, and evaluation of the physical, chemical, and microbiological properties of the suspension.

-The combination of paracetamol and ibuprofen is widely used for the treatment of pain, fever, and inflammation. Paracetamol is a widely used analgesic and antipyretic, while ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that is commonly used for the treatment of pain, fever, and inflammation.

Formulation Development

The formulation development of paracetamol and ibuprofen suspension involves the selection of suitable excipients, such as suspending agents, thickening agents, and flavoring agents. The ratio of paracetamol to ibuprofen is also critical in determining the efficacy and safety of the formulation.

Selection of Excipients

The selection of excipients is critical in the formulation development of paracetamol and ibuprofen suspension. The excipients used in the formulation should be compatible with the active pharmaceutical ingredients (APIs) and should not affect the stability and bioavailability of the APIs.

Optimization of Formulation Composition

The optimization of the formulation composition is critical in the formulation development of paracetamol and ibuprofen suspension. The formulation composition should be optimized to achieve the desired physical, chemical, and microbiological properties of the suspension.

Evaluation of Physical, Chemical, and Microbiological Properties

-The physical, chemical, and microbiological properties of the suspension should be evaluated to ensure that the formulation meets the required standards. The physical properties of the suspension, such as pH, viscosity, and sedimentation volume, should be evaluated. The chemical properties of the suspension, such as assay of paracetamol and ibuprofen, should also be evaluated. The microbiological properties of the suspension, such as total bacterial count and total fungal count, should also be evaluated.

-The formulation development of paracetamol and ibuprofen suspension is a complex process that requires careful selection of excipients, optimization of the formulation composition, and evaluation of the physical, chemical, and microbiological properties of the suspension. The review paper highlights the importance of developing a stable and effective suspension formulation of paracetamol and ibuprofen for pediatric and geriatric patients who have difficulty swallowing tablets.

-Paracetamol (acetaminophen) and ibuprofen are well-established drugs for pain and fever management. While paracetamol primarily acts centrally, ibuprofen exhibits anti-inflammatory action by inhibiting cyclooxygenase (COX) enzymes. Their combination in suspension form provides synergistic effects, offering better efficacy in managing symptoms. However, the formulation development of these drugs poses challenges such as solubility, stability, and taste masking.

2. PHYSICOCHEMICAL PROPERTIES

1. Paracetamol:-

   - Solubility: Poorly soluble in water (14 mg/mL at 25°C). 

   - Stability: Susceptible to hydrolysis and oxidation. 

   - pH range: Stable in mildly acidic to neutral pH.

2. Ibuprofen:-

   - Solubility: Poorly water-soluble (0.021 mg/mL at 25°C). 

   - Stability: Sensitive to photodegradation and oxidation. 

   - pH range: Stable in acidic conditions.

These properties influence the formulation strategy, particularly the choice of solubilizers and stabilizers.

3. FORMULATION CHALLENGES

1. Taste Masking: 

Both drugs have a bitter taste requiring sweeteners and flavoring agents.

2. Poor Water Solubility:-

Techniques such as solubilization with co-solvents, complexation (e.g., with cyclodextrins), or nanosizing may be employed.

3. Physical and Chemical Stability:-

Oxidation, hydrolysis, and precipitation during storage need to be mitigated using appropriate excipients.

4. Drug-Drug Compatibility

In combined formulations, interactions between paracetamol and ibuprofen must be studied.

4. EXCIPIENT SELECTION

1. Suspending Agents: Xanthan gum, sodium carboxymethylcellulose, or carbomers to ensure uniform dispersion. 

2. Sweeteners: Sucrose, sorbitol, or aspartame for palatability. 

3. Preservatives: Methylparaben, propylparaben, or benzoates to prevent microbial growth. 

4. Buffers: Citrate or phosphate buffers to maintain pH stability. 

5. Antioxidants: Ascorbic acid or sodium metabisulfite to prevent oxidation. 

6. Flavoring Agents: Orange, cherry, or strawberry flavors to improve taste acceptability. 

5. PREPARATION METHODS

1. Wet Granulation: Dissolving or dispersing the active ingredients in a suitable vehicle with suspending agents. 

2. Homogenization: High-shear mixing to ensure uniform particle size distribution. 

3. Microencapsulation: Encapsulating drugs to enhance taste masking and stability. 

6. EVALUATION PARAMETERS

1. Physical Appearance: Color, odor, and homogeneity. 

2. pH: Should remain stable within the specified range. 

3. Viscosity: Evaluated using a viscometer to ensure proper flow and resuspendability. 

4. Assay: Drug content must meet pharmacopeial specifications. 

5. Dissolution Studies: To assess drug release profiles. 

6.Stability Testing:- Long-term and accelerated stability studies to ensure shelf life. 

7. RECENT ADVANCES

1. Nanoparticle Suspensions: Enhanced bioavailability using nanocrystals of paracetamol and ibuprofen. 

2. Co-Crystals: Improved solubility and stability through co-crystal technology. 

3. Liquid Crystalline Systems: Enhanced drug delivery by stabilizing hydrophobic drugs. 

8. REGULATORY CONSIDERATIONS

- Compliance with pharmacopeial standards (USP, BP, IP). 

- Ensuring safety and efficacy through rigorous quality control testing. 

- Labeling requirements, including dosage instructions and storage conditions.   

-The development of a stable and effective suspension formulation of paracetamol and ibuprofen requires a comprehensive understanding of their physicochemical properties, excipient interactions, and manufacturing processes. Advances in formulation technologies continue to address the challenges of solubility, stability, and patient compliance, paving the way for more effective drug delivery systems.

-Preformulation is the initial phase of drug development aimed at studying the physicochemical and biopharmaceutical properties of active pharmaceutical ingredients (APIs) and excipients. These studies provide critical insights for designing a stable, effective, and palatable suspension of paracetamol and ibuprofen.

1. Objectives of Preformulation

- To understand the physicochemical properties of paracetamol and ibuprofen. 

- To determine drug-excipient compatibility. 

- To assess solubility and stability for suspension formulation. 

- To select appropriate excipients for achieving desired characteristics. 

2. Physicochemical Properties of APIs

A. Paracetamol

1. Molecular Formula: C8H9NO2 

2. Molecular Weight: 151.16 g/mol 

3. Solubility: Slightly soluble in water, freely soluble in ethanol. 

4. pKa: 9.5 (weakly acidic). 

5. Melting Point: 169–170°C. 

6. Stability: Susceptible to hydrolysis and oxidation; stable under mildly acidic to neutral pH. 

B. Ibuprofen

1. Molecular Formula: C13H18O2 

2. Molecular Weight: 206.28 g/mol 

3. Solubility: Poorly soluble in water, soluble in alcohol and organic solvents. 

4. pKa: 4.9 (weakly acidic). 

5.Melting Point: 75–78°C. 

6. Stability: Sensitive to photodegradation and oxidation; stable in acidic pH. 

3. Preformulation Studies

A. Solubility Studies

- Evaluate solubility in various solvents (water, ethanol, propylene glycol). 

- Use co-solvents, surfactants (e.g., polysorbates), or solubilizing agents (e.g., cyclodextrins) to enhance solubility. 

- Determine solubility at different pH levels to identify optimal pH for suspension. 

B. pH Stability Studies 

- Conduct stability studies at various pH levels (3-7) to identify the pH range where both drugs remain stable. 

- Buffer systems (e.g., citrate, phosphate) are tested for compatibility. 

C. Partition Coefficient (Log P)

- Measure the partition coefficient to understand the lipophilicity and permeability of ibuprofen and paracetamol. 

- Log P of ibuprofen (~3.5) suggests higher lipophilicity compared to paracetamol (~0.46). 

D. Particle Size Analysis

- Determine particle size and distribution to ensure optimal suspension stability and bioavailability. 

- Aim for fine particles (<20 µm) for improved dissolution and uniformity. 

E. Drug-Excipient Compatibility Studies

- Use techniques like Differential Scanning Calorimetry (DSC), Fourier Transform Infrared Spectroscopy (FTIR), and X-ray Diffraction (XRD) to assess interaction. 

- Compatible excipients include: 

  - Suspending agents: Xanthan gum, sodium CMC. 

  - Sweeteners: Sorbitol, sucrose, aspartame. 

  - Preservatives: Sodium benzoate, methylparaben. 

F. Rheological Studies

- Analyze the flow properties of suspending agents to maintain uniformity. 

- Select excipients that provide pseudo-plastic or shear-thinning properties for ease of administration. 

G. Wettability Studies

-Assess the wetting behavior of both drugs to determine the need for wetting agents (e.g., polysorbates). 

H. Stability Studies

- Evaluate the stability of drugs under different environmental conditions (light, temperature, and humidity). 

- Conduct stress tests to identify potential degradation products. 

I. Taste Masking Studies

- Perform sensory evaluation to understand the bitterness level. 

- Use techniques like microencapsulation or the addition of flavors (e.g., cherry, orange) and sweeteners. 

4. Key Considerations for Excipients

- Stability: Ensure no interaction with APIs. 

- Taste: Select excipients to mask the bitterness of APIs. 

- Viscosity: Choose suspending agents for optimal pourability and re-dispersibility. 

- Microbial Stability: Use preservatives to inhibit microbial growth. 

- pH Adjustment: Use buffers to maintain pH stability. 

5. Preformulation Outcomes

1. Ideal pH: Acidic range (~4–6) suitable for ibuprofen stability and compatible with paracetamol. 

2. Suspending Agent: Xanthan gum or sodium CMC provides optimal viscosity and stability. 

3. Taste Masking: Sucrose and artificial sweeteners with fruit flavors enhance palatability. 

4.Stability Enhancers: Use of antioxidants like ascorbic acid or sodium metabisulfite prevents oxidation. 

5. Preservatives:-Methylparaben and sodium benzoate ensure microbiological safety. 

CONCLUSION: -

The formulation development of paracetamol and ibuprofen suspensions aims to create an effective and stable combination therapy for pain and fever management. Marketed products like Combiflam, Ibujesic Plus, Adiflam Plus, Aldigesic Plus, and Ibuflamar Plus serve as benchmarks for dose comparison, safety, efficacy, and compliance. These suspensions are designed to meet pediatric and adult dosing requirements, ensuring optimal therapeutic outcomes while minimizing adverse effects.

REFERENCES

1. Arana A, Morton NS, Hansen TG. Treatment with paracetamol in infants. Acta Anaesthesiol. Scand.. 2001;45:20–29.
2. Anderson BJ, Holford NH, Woollard GA, Chan PL. Paracetamol plasma and Cerebrospinal fluid pharmacokinetics in children. Br. J. Clin. Pharmacol.1998;46:237–243.
3. Paul IM, Walson PD. Acetaminophen and ibuprofen in the treatment of pediatric Fever: a narrative review. Curr. Med. Res. Opin.. 2021;37:1363–1375.
4. Ruiz F, Vallet T, Dufaÿ Wojcicki A, et al. Dosage form suitability in vulnerable Populations: a focus on paracetamol acceptability from infants to centenarians. PLoS One. 2019;14:e0221261.
5. Klingmann V, Vallet T, Münch J, et al. Dosage forms suitability in pediatrics:Acceptability of analgesics and antipyretics in a German hospital. Pharmaceutics.2022:14.
6. Flanagan T. Potential for pharmaceutical excipients to impact absorption:a Mechanistic review for BCS class 1 and 3 drugs. Eur. J. Pharm. Biopharm.2019;141:130–138.
7. Questions & Answers: positions on specific questions addressed to the Pharma-Cokinetics Working Party (PKWP): European Medicines Agency; 2015.
8. Guideline on bioanalytical method validation: European Medicine Agency; 2011.
9. Anderson BJ, Woollard GA, Holford NH. A model for size and age changes in the Pharmacokinetics of paracetamol in neonates, infants and children. Br. J. Clin.Pharmacol.. 2000;50:125–134.
10. Fassihi AR, Dowse R, Robertson SSD. Influence of sorbitol solution on the Bioavailability of theophylline. Int. J. Pharm.. 1991;72:175–178.
11. Chen ML, Straughn AB, Sadrieh N, et al. A modern view of excipient effects on Bioequivalence: case study of sorbitol. Pharm. Res.. 2007;24:73–80.
12. Van Os S, Relleke M, Piniella PM. Lack of bioequivalence between generic Risperidone oral solution and originator risperidone tablets. Int. J. Clin. Pharma-Col. Ther.. 2007;45:293–299. Rowe, R. C., Sheskey, P. J., & Quinn, M. E. (2009). *Handbook of Pharmaceutical Excipients*.
13. 13.Allen, L. V., & Ansel, H. C. (2014). *Ansel’s Pharmaceutical Dosage Forms and Drug Delivery Systems*.
14. ICH Q1A(R2) Guidelines on Stability Testing of New Drug Substances and Products. Recent research articles from journals like *International Journal of Pharmaceutics*, *Journal of Pharmaceutical Sciences*, etc.
15. Ahmed A, Ali S , Hassan F, Haque N,2001, „Evaluation of acetaminophen tablets by control Test?, Pakistan journal of pharmaceutical science,vol 14(2),pp.47-55
16. Angho M, Okor R,2007,?A comperative study of the dissolution characteristics of capsule and Tablet dosage forms of melt granulations of paracetamol-diluent effects?,Acta Poloniae Pharmaceutica-Drug Research,vol 64(1), pp.73-79
17. Gangwar S, Singh S, Garg G, Garg V, Sharma P, 2010,? To compare the disintegrating property Of papaya and sago starch in paracetamol tablets?, International journal of pharmacy and Pharmaceutical science, vol 2, pp.1-3
18. Hanumankishore B, Venkareswararao T, Sankar K, Rao B, 2011, „ Studies on dissolution rate of Paracetamol tablets by using different polymers?, Journal of global trends in Pharmaceutical science, vol 2, pp.1-10.
19. Ngwuluka N, Ldiakhoa B, Nep E, Okafor L, 2010, „ Formulation and evaluation of paracetamol Tablets manufactured using the dried fruit of phoenix dactylifera Linn as an excipient? Research in pharmaceutical biotechnology, vol 2 (3), pp.25-32
20. Karmakar P, Kibria M, 2012,? In vitro comperative evaluation of quality control parameters Between paracetamol and paracetamol/caffeine tablets available in Bangladesh?, International current pharmaceutical journal,vol 1, pp.1-6.
21. Gilbert S, Neil R, Anderson, 1986, The theory and practice of industrial pharmacy, 3rd edition, pp.300
22. Seitz J, Flessland G, 1965,?Evaluation of physical properties of compressed tablets? pp 1353-1357
23. IARC monographs,1990,vol 73, pp. 402-438 Munsterhjelm E,2006,?Charecterization of inhibition of platelet function by paracetamol and its Interaction with diclofenac and parecoxib? Literarum radices amaras,pp.9-39
24. Munsterhjelm E, Munsterhjelm NM, Ylikorkala O, 2005,Dose dependent inhibition of platelet Function by acetaminophen in healthy volunteers, anesthesiology,pp 103- 712.
25. Smith H, 2009, Potential analgesic mechanism of acetaminophen, Pain physician,vol 12, pp. 269-280
26. Forrest JA, Clements JA, Prescott LF, 1982, „Clinical pharmacokinetics of paracetamol?, UK Pubmed central, vol 7 (2), pp. 93-107
27. Burke, A., Smyth, E., & FitzGerald, G. A. (2005). Analgesic-Antipyretic Agents; Pharmacotherapy of Gout. In L.B. Brunton, J.S Lazo, & K.L. Parker (Eds.), Goodman &        Gilman’s the pharmacological basis of therapeutics. (11th ed., pp. 693). New York: McGraw-Hill